CEL-SCI reports clinical hold on head and neck cancer study
CEL-SCI announcedit has received verbal notice from the FDA that its Multikine (Leukocyte Interleukin Injection) Phase 3 clinical trial in advanced primary head and neck cancer has been placed on clinical hold. The study currently has about 926 patients enrolled.
September 27, 2016